Loading...
XNAS
TNDM
Market cap1.15bUSD
Oct 20, Last price  
16.52USD
1D
0.85%
1Q
-2.31%
Jan 2017
-23.16%
IPO
-91.42%
Name

Tandem Diabetes Care Inc

Chart & performance

D1W1MN
XNAS:TNDM chart
P/E
—
P/S
1.13
EPS
—
Vol. 1Y
73.93%
Shs. 5Y
1.98%
Rev. 5Y
15.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.01b
+7.93%
02,474,69829,006,63849,722,00072,850,00084,248,000107,601,000183,866,000362,305,000498,830,000702,799,000801,217,000747,718,000940,203,0001,014,736,000
Net income
-205m
L+113.18%
-25,509,824-33,015,085-63,138,849-79,524,000-72,418,000-83,447,000-73,033,000-122,611,000-24,753,000-34,382,00015,566,000-94,594,000-222,611,000-96,025,000-204,710,000
CFO
-10m
L
-21,546,786-33,471,166-47,756,651-61,378,000-58,764,000-61,173,000-66,136,000-8,319,00041,906,00024,669,000111,359,00050,464,000-31,810,00024,225,000-9,721,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Key people

President, Chief Executive Officer, Director · since 2019
Jean-Claude Kyrillos
Chief Operating Officer, Executive Vice President · since 2024
Elizabeth Gasser
Executive Vice President and Chief Strategy and Product Officer · since 2023
Mark Novara
Executive Vice President and Chief Commercial Officer · since 2023
Leigh Vosseller
Chief Financial Officer, Executive Vice President, Treasurer · since 2018
Rick Carpenter
Chief Technical Officer · since 2021
Susan Morrison
Executive Vice President, Chief Administrative Officer · since 2017
Shannon Hansen
Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary · since 2024
Sandra Beaver
Independent Director · since 2025
Myoung Cha
Independent Director · since 2022
Independent Director · since 2020
Joao Malagueira
Independent Director · since 2022
Kathleen McGroddy-Goetz
Independent Director · since 2020
Rebecca Robertson
Independent Chairman of the Board · since 2023
Rajwant Sodhi
Independent Director · since 2021
Independent Director · since 2013
IPO date
Nov 13, 2013
Employees
2,600
Domiciled in
US
Incorporated in
US
Legal address
C/o Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT